In the new week, the trading of new crown detection concept stocks continued to be hot.
Today (January 17th), Jiu’an Medical (002432.SZ) opened the daily limit again and reported 82.81 yuan, which was the fifth consecutive daily limit.
On the news, Jiu’an Medical announced on the evening of the 16th that its subsidiary iHealth New Crown Antigen Rapid Detection POC Professional Edition kit product obtained FDA (US Food and Drug Administration) EUA (Emergency Use Authorization). The product must be tested by professional medical staff or personnel who are skilled in using the kit product in the scene of on-site care to collect anterior nasal swab samples for testing.
This means that iHealth’s new crown detection products have another base.
On November 6, 2021, Jiu’an Medical’s new crown antigen home self-testing OTC kit was authorized by the FDA EUA. The demander purchases without a prescription, and the products are sold through channels such as e-commerce, pharmacies, and supermarkets in the United States. After the news was released, the medical device company Jiu’an Medical “stained” the concept of new crown detection, and its stock price rose to 80 yuan from June to 80 yuan in just two months.
Last week, Jiu’an Medical disclosed two major contract announcements for the daily operation of the home self-test kit, including the contracts and orders received by the US subsidiary iHealth and New York State and Massachusetts “Procurement Contract” signed by American HHS and American ACC, which purchases on its behalf. The total transaction value of the two contracts is approximately RMB 8.517 billion.
With the frequent release of good news, the stock price has become “crazy”, but the reporter noticed that Jiu’an Medical, which has been concerned by the exchange due to information disclosure issues, has also increased the frequency of risk warnings.
For example, in the announcement of abnormal trading fluctuations and risk warning issued on the 16th, Jiu’an Medical reminded the risk that two contracts or orders could not be fulfilled as scheduled or in full under the influence of various external factors. Among them, a particularly noteworthy sentence is that “the U.S. government has the right to suspend the contract signed by the company’s U.S. subsidiary and the U.S. HHS (executed by the U.S. ACC representative) at any time due to its own factors, and there is uncertainty as to whether the contract can be fully implemented.”
In addition, the staff of Jiu’an Medical Securities Department also told the “Daily Economic News” reporter that the company is fully reminding risks in accordance with the regulations of the letter and disclosure, and investors should invest rationally.
Source of cover image: Photo Network-500486532
